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Recent findings link metabolic transformation of cancer cells to aberrant functions of mitochondrial uncoupling proteins (UCPs).
By inducing proton leak, UCPs interfere with mitochondrial synthesis of adenosine 50-triphosphate, which is also a key determinant of
glycolytic pathways. In addition, UCP suppress the generation of superoxide, a byproduct of mitochondrial electron transport and a
major source of oxidative stress. The near ubiquitous UCP2 becomes highly abundant in some cancers and may advance metabolic
reprogramming, further disrupt tumour suppression, and promote chemoresistance. Here we review current evidence to suggest
that inhibition of mitochondrial uncoupling may eliminate these responses and reveal novel anti-cancer strategies.
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Cancer cells are exposed to seemingly adverse conditions such as
hypoxia, nutrient limitation and immune defence mechanisms.
Those surviving adaptive cancer cells have successfully responded
to the selection pressure of the host microenvironment by
subversive molecular changes that impact mitochondrial functions
and promote glycolysis. These changes foster metabolic flexibility,
autonomous growth, abrogation of programmed cell death,
sustained angiogenesis and immune evasion (Hanahan and
Weinberg, 2000). In clinical practise, these adaptive cellular
responses might also manifest as chemoresistance. A better
understanding of the molecular mechanisms that facilitate cancer
cell survival should help guide novel therapeutic strategies.
MITOCHONDRIAL HOMEOSTASIS AND
UNCOUPLING PROTEINS (UCPS)
In normal cells, mitochondria integrate molecular pathways of
energy production and biosynthesis, maintain redox balance,
regulate intracellular calcium signalling and participate in cell fate
decisions, including the initiation and execution of apoptosis.
Mitochondria also has critical roles in the survival strategy of
cancer cells (Frezza and Gottlieb, 2009).
Within mitochondria, the machinery of oxidative phosphoryla-
tion carries out high-yield adenosine 50-triphosphate (ATP)
synthesis at the expense of generating reactive oxygen species
(ROS; Figure 1). Reducing equivalents generated by the tricar-
boxylic acid (TCA) cycle or by b-oxidation of fatty acids provide
the electrons that are transported along the electron transfer
complexes I–IV of the inner mitochondrial membrane (Nicholls and
Ferguson, 1992). The energy of this process is coupled with outward
translocation of protons across the inner mitochondrial membrane,
defined as the mitochondrial membrane potential (Dcm). Re-entry
of protons to the mitochondrial matrix drives the ATP synthase
(complex V) that converts adenosine 50-diphosphate (ADP) to
ATP. To complete the process, adenine nucleotide translocase
(ANT) exchanges ADP for ATP across the mitochondrial inner
membrane (Nicholls and Ferguson, 1992).
The mitochondrial electron transport chain (ETC) is an
inherent source of intracellular ROS (Turrens, 2003). Although
transported electrons are destined to reach molecular oxygen
at the level of cytochrome oxidase (complex IV), some electrons
escape the ETC at earlier steps and form superoxide, a major
ROS variant, by single electron reduction of molecular oxygen
(Brand et al, 2004). The levels of superoxide generation are
high if the electron flow becomes sluggish and the half-life
of mobile electron carriers is prolonged. This may occur when
there is a supply/capacity imbalance of proton movements
either due to accelerated metabolic rates (increased supply) or
due to partial impairment of the mitochondrial respiratory
complexes including the ATP synthase (decreased capacity;
Skulachev, 1998).
As superoxide production is very sensitive to changes in Dcm,
mitochondrial ROS levels can be effectively controlled by the rate
of proton re-entry (Brand, 1990). A considerable amount of
protons may bypass the ATP synthase pathway and leak back to
the mitochondrial matrix. This seemingly wasteful dissipation of
the proton-motive force as heat energy is termed mitochondrial
uncoupling (Brand, 1990). More important, this event is mediated
by UCPs and represents the first line of antioxidant defence aimed
at resolving mismatched outward and inward proton fluxes
(Skulachev, 1998; Brand and Esteves, 2005).
The UCPs belong to the mitochondrial anion transporter
superfamily located in the inner mitochondrial membrane (Boss
et al, 1999). The UCP1 is the longest known UCP, confined to
brown adipose tissue where it is highly abundant and accounts for
adaptive thermogenesis. The UCP2, a more recently identified
member of the UCP family has gained attention, as it is essentially
ubiquitous and has also been shown to mediate proton
conductance (Krauss et al, 2005; Nubel and Ricquier, 2006).
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www.bjcancer.comThe UCP2 is much less abundant than UCP1 and has no apparent
role in thermogenesis. Instead, UCP2 has been implicated in free
radical scavenging relevant to diverse physiological and patholo-
gical processes, including obesity, neurodegenerative diseases,
ageing and cancer (Nubel and Ricquier, 2006; Baffy, 2010). The
antioxidant effect of UCP2 has been well documented in a variety
of in vitro and in vivo experimental systems using UCP2
overexpression, genetic ablation and pharmacological inhibition
(Arsenijevic et al, 2000; Collins et al, 2005; Derdak et al, 2008).
Interestingly, UCP2-mediated proton leak requires activation by
superoxide and lipid peroxidation derivatives such as 4-hydro-
xynonenal and other reactive alkenals (Echtay et al, 2002; Brand
et al, 2004). Thus, UCP2 may be considered primarily as a sensor
and suppressor of mitochondrial ROS, with increasing functional
impact at increasing levels of oxidative stress.
Although modulation of Dcm by inducible proton conductance
is a prerequisite to UCP2-mediated control of ROS, lowering the
proton-motive force by uncoupling has additional effects on
cellular energy metabolism (Figure 2A). To sustain mitochondrial
redox homeostasis, metabolite flux through the TCA cycle must be
balanced with NADH re-oxidation rates by mitochondrial respira-
tion. As the electron transport is coupled with proton transloca-
tion, biosynthetic and bioenergetic pathways are tightly linked and
subject to regulatory constraints of mitochondrial respiration
(Ainscow and Brand, 1999; Cortassa et al, 2009). Thus, UCP2 may
prove pivotal in dissociating oxidative phosphorylation from other
mitochondrial functions (Figure 2B). As it turns out, this
dissociation is a key feature of metabolic and energetic transfor-
mation in cancer cells (DeBerardinis et al, 2008; Vander Heiden
et al, 2009).
UCP2 AND METABOLIC REPROGRAMMING IN CANCER
In cancer cells, mitochondrial functions are modified to meet the
special needs and liabilities of rapid and uncontrolled proliferation
(DeBerardinis et al, 2008; Hsu and Sabatini, 2008). Perhaps the
most prominent of these changes is the metabolic switch to aerobic
glycolysis also known as the Warburg effect. Cancer cells
increasingly favour glycolysis over mitochondrial oxidative
phosphorylation as the source of ATP. This bioenergetic shift
from mitochondria to the cytosol results in an increasingly
aggressive cancer phenotype, indicating that aerobic glycolysis
with generation of lactate is a successful adaptation strategy
(Vander Heiden et al, 2009).
The molecular mechanisms underlying the Warburg effect and
linking it to uncontrolled cell growth and proliferation are
incompletely understood. There is mounting evidence to suggest
cross-talk between changes in energy metabolism and oncogenic
signalling pathways that collectively drive adaptive responses in
cancer cells (Hsu and Sabatini, 2008; Vander Heiden et al, 2009).
Several non-exclusive concepts have been proposed to explain the
emergence of glycolytic phenotype in cancer. Enhanced glycolysis
may allow high-rate ATP production with a selective advantage
when competing for limited resources (Pfeiffer et al, 2001). These
pathways feed into the pentose phosphate pathway to provide
building blocks for nucleotide synthesis and NADPH for
antioxidant defence; control the intrinsic apoptosis pathway via
hexokinase-mediated inhibition of the voltage-dependent anion
channel; and by producing excess lactate may sustain acidic
microenvironments that are less habitable for normal cells,
suppress immune responses and facilitate invasive growth
(Gatenby and Gillies, 2004; DeBerardinis et al, 2008; Hsu and
Sabatini, 2008).
One additional benefit of the Warburg effect is diversion of
substrates from the ETC that may diminish the rate of
mitochondrial ROS production (Brand and Hermfisse, 1997).
Cancer cells often exhibit increased levels of intracellular ROS with
complex and controversial biological effects (Burdon, 1995;
Hussain et al, 2003). The ROS induce genomic instability and
stimulate oncogenic pathways that promote cancer cell growth and
survival. However, excessive and sustained ROS levels may lead to
cell growth arrest, senescence and cell death by activating
alternative signalling pathways and causing fatal macromolecular
damage (Martindale and Holbrook, 2002; Hussain et al, 2003).
Thus, effective regulation of intrinsic and treatment-induced
oxidative stress is a critical ability of the surviving cancer cells
that may acquire various forms of antioxidant defence (Martindale
and Holbrook, 2002).
There is increasing evidence that UCP2 expression patterns are
linked to cancer and may further modulate energy metabolism in
response to high ROS levels (Baffy, 2010). Thus, UCP2 expression
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Figure 1 Oxidative phosphorylation and mitochondrial uncoupling. Substrate-derived electrons from glucose and fatty acid metabolism flow through
complexes I–IV of the electron transport chain embedded in the mitochondrial inner membrane and the energy of this process is used for pumping protons
(H
þ) from the matrix into the intermembrane space. The resulting proton gradient sustains the mitochondrial membrane potential (Dcm), which drives
ATP synthase (oxidative phosphorylation). The ATP and ADP are exchanged between the matrix and cytoplasm via ANT. Proton conductance (proton
leak) induced by uncoupling proteins (exemplified here by the ubiquitous UCP2) competes for the same proton gradient, resulting in lower values of (Dcm)
and diminished production of ATP. Decrease in Dcm accelerates electron transport and mitochondrial respiration, limiting the odds for electron escape and
production of superoxide, a prototype of ROS. Activation of UCP2 by ROS (purple dotted arrow) provides an important negative feedback mechanism for
the regulation of Dcm and mitochondrial oxidant production. The colour reproduction of this figure is available at the British Journal of Cancer online.
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degree of oxidative stress and neoplastic changes along with the
‘two-hit’ hypothesis and in the setting of adenoma–carcinoma
transformation (Horimoto et al, 2004). The Warburg effect in
certain leukaemia cells is linked to UCP2 activation (Samudio et al,
2008). Drug-resistant sub-lines of various cancer cells exhibit
increased levels of UCP2, lower mitochondrial membrane potential
and diminished susceptibility to cytotoxic effects (Harper et al,
2002). Overexpression of UCP2 in HepG2 human hepatoma cells
limits oxidative stress and apoptosis in response to various
challenges (Collins et al, 2005). Moreover, xenografts of UCP2-
overexpressing HCT116 colon cancer cells retain growth in nude
mice receiving chemotherapy, providing strong evidence that
UCP2 upregulation is a plausible mechanism of chemoresistance in
such studies (Derdak et al, 2008). These observations indicate that
UCP2 is more than just a marker of increased ROS levels and
serves as an important tool for reducing oxidative stress in
adapting cancer cells.
What makes UCP2 an appealing molecular tool of adaptation for
cancer cells? The evolutionary raison d’e ˆtre of UCP2 seems difficult
to comprehend, as increased inner membrane proton conductance
not only allows efficient control of intracellular ROS, but it also
disrupts oxidative phosphorylation. Importantly, ROS production
is much more sensitive to uncoupling-mediated changes in Dcm
than ATP synthesis (Miwa and Brand, 2003). Nonetheless,
markedly enhanced UCP2 expression in non-transformed cells
(primarily induced by fatty acids) may become a significant
drawback as shown in pancreatic b cells of obesity-associated
(type 2) diabetes. Here upregulated UCP2 leads to decreased ATP
production and loss of glucose-stimulated insulin secretion (Zhang
et al, 2001). Similarly, UCP2 abundance in hepatocytes is
associated with limited ATP stores and energetic vulnerability of
fatty liver (Chavin et al, 1999).
Curiously, the impact of UCP2 on cellular ATP production is not
apparent in cancer cells that have a competitive growth advantage
over normal differentiated cells (Derdak et al, 2008). Transformed
cells may have substantial UCP2 upregulation seemingly without
energetic compromise. This is predictable in cancer cells that
exhibit high-rate ATP production by glycolysis, for as long as
glucose remains available (Vander Heiden et al, 2009). Consump-
tion of surplus ATP may in fact promote the Warburg effect in
rapidly proliferating cancer cells by relieving allosteric inhibition
of phosphofructokinase (PFK), a major enzyme controlling
glycolysis (Israelsen and Vander Heiden, 2010).
A recently identified mechanism that indirectly consumes ATP
and favors glycolysis is the heightened expression of endoplasmic
reticulum ectonucleoside triphosphate diphosphohydrolase 5 in
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Figure 2 The UCP2 and energy metabolism. (A) In normal cells,
catabolic and anabolic pathways intersecting in the mitochondrial TCA
cycle are balanced by redox power. The NADH derived from substrate
breakdown is primarily re-oxidised by mitochondrial respiration (electron
transport chain). This process is coupled to ATP synthesis and depends on
the magnitude of Dcm and availability of ADP. This may limit TCA flux and
macromolecular biosynthesis rates. (B) In dysplastic or cancer cells, proton
conductance induced by upregulated mitochondrial uncoupling (UCP2)
lowers Dcm and not only disrupts both ATP synthesis and ROS generation
(dotted arrows), but also dissociates the TCA cycle and upstream
metabolic pathways from the constraints of oxidative phosphorylation.
Under these conditions, the impact of glycolysis on bioenergetics and
biosynthesis may increase without the burden of concurrently high
mitochondrial ROS production (solid thick arrows). (C) Mitochondrial
uncoupling may support biosynthesis in rapidly proliferating cells by an
additional mechanism. High glycolytic rates in cancer cells may result in
surplus ATP and feedback inhibition of glycolysis. This obstacle may be
removed if ANT exports glycolytic ATP into the mitochondria where it is
hydrolysed by ATP synthase. As reverse functioning ATP synthase pumps
protons out of the matrix, ATP hydrolysis may sustain Dcm in mitochondria
with impaired or futile (uncoupled) respiration. Therefore, UCP2 may
create a mitochondrial ATP sink to boost glycolysis in cancer cells.
According to this model, the sum of UCP2 and ANT effects may determine
prevailing Dcm and account for any variability seen in cancer cells.
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This organelle-associated UDPase promotes N-glycosylation of
newly synthesised proteins and facilitates their correct folding in
the endoplasmic reticulum by hydrolysing uridine 50-diphosphate
to uridine 50-monophosphate (Israelsen and Vander Heiden, 2010).
This activity is linked to ATP hydrolysis in the cytosol and has a
positive effect on glycolytic rates (Fang et al, 2010). It is tempting
to speculate that depletion of cytosolic ATP by UCP2-mediated
uncoupling may similarly modulate PFK activity and thereby boost
glucose metabolism in cancer.
Paradoxically, mitochondria may consume substantial amounts
of glycolytic ATP to maintain critical homeostatic functions
associated with Dcm if the proton-pumping activity of ETC
becomes insufficient due to impaired respiration or in response to
chemically induced uncoupling (Desquiret et al, 2006; Chevrollier
et al, 2010). Under these conditions, the role of ATP synthase is
reversed such that it contributes to Dcm by pumping out protons
at the expense of ATP hydrolysis. To assist this process, cytosolic
ATP is transferred to the matrix side by ANT2, an ANT isoform
mainly expressed corresponding to the glycolytic activity in
rapidly growing, undifferentiated cells (Chevrollier et al, 2010).
Whether increased UCP2 expression helps cancer cells to trans-
form mitochondria into a sink of glycolytic ATP by invoking the
reverse function of ANT2 and ATP synthase remains to be seen. In
addition, it is reasonable to speculate that reverse operating ANT,
fuelled by glycolytic ATP, may provide a mechanism to counteract
the effect of UCP2-mediated uncoupling. This might underpin the
controversy about higher Dcm and impacts on cancer cells that are
observed in different experimental systems (Figure 2C).
Evidence is gathering that inhibition of UCP2 may thwart
metabolic adaptation and antioxidant defence mechanisms in
cancer cells. Drug resistance is weakened by genipin in MX2
leukaemia cells that have abundant mitochondrial UCP2 (Mailloux
et al, 2010). Genipin, an extract from Gardenia jasminoides,i sa
traditional Chinese remedy for type 2 diabetes that inhibits UCP2-
mediated proton leak (Zhang et al, 2006). In MX2 cells, genipin
decreases oligomycin-insensitive (uncoupling dependent) mito-
chondrial oxygen consumption and increases intracellular ROS
levels in response to pro-oxidant agents such as menadione,
doxorubicin and epirubicin (Mailloux et al, 2010). Similarly,
genipin renders HT-29 and SW-620 human colon cancer cells
more sensitive to cisplatin, as indicated by higher rates of
mitochondrial ROS production and by decreased viability
(Santandreu et al, 2010). These findings suggest that ROS toxicity
induced by limiting inducible proton conductance via inhibition of
UCP2 may improve responsiveness to conventional cancer drugs,
identifying a potential novel approach to treat chemoresistance.
In keeping with the notion that partial breakdown of Dcm is the
pivotal mechanism behind the antioxidant and anti-apoptotic
effects of UCP2 in cancer cells, many of these effects are
reproduced with the use of chemical uncouplers (protonophores).
Protonophores are artificial compounds that allow protons to
cross the lipid bilayer without the need for a channel or
transporter. As recently reported, the protonophore carbonylcya-
nide p-trifluoromethoxyphenylhydrazone (FCCP) blocks the anti-
tumour activity of various topoisomerase inhibitors and cisplatin
in colon cancer cells (Derdak et al, 2008; Santandreu et al, 2010).
Further studies will reveal to what extent various aspects of
metabolic reprogramming in cancer cells can be modulated by
artificial uncouplers.
UCP2 AND THE P53 RESPONSE IN CANCER
The impact of UCP2 on mitochondrial homeostasis is potentially
so pervasive that it is difficult to identify a specific molecule or
mechanism as the downstream effector of altered uncoupling in
cancer cells. However, there is increasing evidence that p53, the
main guardian of genomic integrity is a functional target of UCP2
(Figure 3). Modulation of mitochondrial ROS production by UCP2
may drive this interaction since stabilisation and activation of p53
is responsive to intracellular ROS (Lavin and Gueven, 2006).
Depending on the level of oxidative stress, p53 may activate
antioxidant or pro-oxidant mechanisms to allow cell growth arrest
and damage repair or to initiate cell death pathways (Sablina et al,
2005). This dichotomy of p53-mediated cell fate decisions reflects
the Janus-like pleiotropy of ROS biology. Although excessive
accumulation of ROS may create a positive feedback loop for p53
and shift tumour suppressor mechanisms from repair to demise
(Liu et al, 2008), UCP2 is likely to alter the spectrum of p53
responses by modulating ROS balance and assist the survival of
cancer cells.
Several lines of evidence corroborate an opposing relationship
between mitochondrial uncoupling and p53. First, UCP2 over-
expression and diminished ROS levels in colon cancer cells
interfere with post-translational phosphorylation of p53 by stress-
activated protein kinases at the critical Ser
15, Ser
33 and Ser
46
residues of its NH2 transactivation domain (Derdak et al, 2008).
Second, p53 favors oxidative phosphorylation over glycolysis by
regulating the transcription of several target genes, including
synthesis of cytochrome oxidase 2, Tp53-induced glycolysis and
apoptosis regulator, phosphoglycerate mutase and glucose trans-
porter 1 (Vousden and Ryan, 2009), whereas UCP2 has a
contrasting effect on cellular energy metabolism (Samudio et al,
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Figure 3 UCP2 and feedback regulation of p53. The tumour suppressor
p53 controls metabolic pathways through multiple mechanisms. Transcrip-
tional activation of SCO2 augments the capacity of mitochondrial electron
transport, which is a major source of ROS (solid red lines). In addition, a
fraction of p53 translocates to the mitochondrial matrix and directly inhibits
MnSOD, further increasing ROS (dotted red lines). Metabolic stress
resulting from these events promotes p53 stabilisation. Thus, pro-oxidant
effects of p53 are regulated by multiple feed-forward amplification loops.
The UCP2 is also activated by ROS (solid purple line) and may block these
p53 responses by modulating the mitochondrial membrane potential
(Dcm) and breaking ROS-mediated p53 activation as well as interfering
with p53 translocation to the matrix. In a negative regulatory loop,
differential targeting of TIGAR, PGM and GLUT1 genes by p53 may diminish
glycolytic flux and NADH-mediated binding to NQO1, which would
otherwise protect p53 from ubiquitin-independent degradation (solid blue
lines). Because of higher mitochondrial respiratory rates, UCP2 may
increase NADH shuttling to the mitochondria (dotted purple line),
attenuate NQO1 activity and promote p53 degradation. The colour
reproduction of this figure is available at the British Journal of Cancer online.
Mitochondrial recoupling in cancer therapy
G Baffy et al
472
British Journal of Cancer (2011) 105(4), 469–474 & 2011 Cancer Research UK2008). Thus, UCP2-overexpressing cancer cells increasingly display
the Warburg effect (Derdak et al, 2008), and siRNA-mediated
UCP2 knockdown leads to reversal of the glycolytic phenotype
(Samudio et al, 2008). Third, translocation of p53 to mitochondria,
an important step in the intrinsic apoptotic pathway, is blocked by
the uncoupling action of FCCP in JB6 skin cells, whereas UCP2
knockdown promotes p53 translocation (Wang et al, 2010). This
latter finding indicates that uncoupling may modulate mitochon-
drial protein trafficking in agreement with the notion that Dcm is a
key determinant of the efficiency and rate by which nuclear-
encoded proteins reach their mitochondrial destination (Martin
et al, 1991).
Recent reports suggest that modulation of ROS levels is not the
only mechanism by which UCP2 may affect cancer biology.
Cellular abundance of p53 is primarily regulated by its rapid
degradation, in part via an ubiquitin-independent 20S proteasomal
pathway, which rapidly proceeds unless prevented by NAD(P)
H-dependent binding of p53 to NAD(P)H:quinone oxidoreductase 1,
a cytoplasmic flavone-containing quinone reductase (Tsvetkov
et al, 2009). Accordingly, low reducing power promotes p53
degradation, whereas high reducing power favors p53 stabilisation
(Tolstonog and Deppert, 2010). As mitochondrial uncoupling
stimulates the rate of electron transport and helps recycling
cytosolic NADH into NADþ, UCP2 may promote a redox balance
that favors p53 degradation. One may therefore speculate that 20S
proteasomal degradation is yet another process of metabolic
sensing by which UCP2 may oppose p53 responses and support
cancer cell survival.
It is estimated that about 60% of all human cancers harbour
gain-of-function (dominant negative) or loss-of-activity p53
mutations, whereas in the remaining cases the function of wild-
type p53 is disrupted by additional mechanisms (Harris and
Levine, 2005). On the basis of available data, we may assume that
UCP2 contributes to the dysfunction of wild-type p53 and
targeting mitochondrial uncoupling by UCP2 inhibition or by
some other ways may help restore the functions of p53 unless this
is wholly incapacitated by mutations. Further studies are necessary
to determine whether UCP2-mediated changes in cancer cells have
a measurable impact on mutated p53, which could provide
additional targets for anti-cancer therapy.
PERSPECTIVES
So far, mitochondrial uncoupling in malignancy has been the
interest of a relatively small group of investigators. There should
be cautious optimism about UCP2 entering centre stage and
becoming a novel therapeutic target in cancer. Selective inhibition
of UCP2 may cancel many benefits of metabolic reprogramming in
cancer cells. However, a number of technical difficulties need to be
resolved before a feasible strategy can be developed for controlling
UCP2 in particular, and mitochondrial uncoupling in general. The
UCP2 is a ubiquitous protein with low tissue abundance and
sheltered cellular localisation (Brand and Esteves, 2005; Krauss
et al, 2005). Loss of UCP2 function has been shown to result in
dysfunction of normal cells, questioning the safety margin of
inhibition without selective targeting (Arsenijevic et al, 2000;
Nubel and Ricquier, 2006; Baffy, 2010). This may be cause for
particular concern due to excessive activation of immune cells with
considerable UCP2 abundance at baseline (Arsenijevic et al, 2000).
Crossreactivity of putative inhibitors with other UCPs should also
be considered. Development of mitochondria-targeted inhibitors
has been further hindered by the fact that the crystal structure of
UCP2 is not available. Genipin and derivatives hold promise, but
the precise molecular mechanism of genipin-mediated UCP2
inhibition and potential side effects from the crosslinking activity
of genipin remain to be elucidated (Zhang et al, 2006; Mailloux
et al, 2010).
In an attempt to identify new and selective small-molecule
inhibitors of mitochondrial uncoupling, a very recent report
describes chromane derivatives that may act as a surrogate of the
inhibitory purine nucleotides (e.g., ADP and guanosine 50-dipho-
sphate) that bind deep inside the a-helical bundle core of UCPs
(Rial et al, 2011). Chromanes inhibit basal proton conductance of
UCP1 and UCP2 and sensitise HT-29 colon cancer cells to
commonly used chemotherapeutic agents such as cisplatin and
doxorubicin (Rial et al, 2011).
Altered cellular metabolism wields critical adaptive power in
cancer cells. Changes in bioenergetics and biosynthesis sustain
loops of reinforcement with oncogenic signalling pathways,
rendering selected clones of cancer cells increasingly difficult to
destroy. The robust strategy of unremitting growth and prolifera-
tion defines major attributes of energy metabolism in cancer,
whereas it allows heterogeneity and redundancy that support
successful defection. The UCP2 appears to be centrally positioned
in this scheme as a potential modulator of redox balance, ATP
synthesis, oxidative stress, intracellular oxygen distribution,
apoptosis and mitochondrial protein trafficking. Different cancer
cells may exploit different facets of mitochondrial uncoupling.
Now we have to resolve how, which, and when to recalibrate in
order to reap the most therapeutic benefit.
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